Inhibition of the tumor-expressed metabolizing enzyme CYP2J2, could be a novel clinical strategy to improve TKI efficacy and to decrease the delay before relapse reflecting beta-lactamase inhibition that is a classical strategy to avoid antibiotic degradation and resistance. Here, LACTB is linked to neoplasm.